C4 Therapeutics Inc. (CCCC)
2.50
-0.21 (-7.75%)
At close: Mar 03, 2025, 12:13 PM
C4 Therapeutics Cash Flow Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
| Net Income | -132.49M | -128.18M | -83.89M | -66.33M | -34.1M | -15.71M |
| Depreciation & Amortization | 1.88M | 1.68M | 1.49M | 1.62M | 1.59M | 1.27M |
| Stock-Based Compensation | 27.23M | 30.02M | 21.51M | 3.43M | 1.64M | 582K |
| Other Working Capital | 3.12M | -17.69M | -25.05M | -12.2M | -3.23M | 81.03M |
| Other Non-Cash Items | 3.48M | 7.32M | 2.13M | 1.63M | 1.14M | 2.37M |
| Deferred Income Tax | n/a | n/a | 1.88M | 5.58M | 350K | 66K |
| Change in Working Capital | -6.94M | -16.78M | -30.09M | -13.18M | 84.98M | -5.56M |
| Operating Cash Flow | -106.84M | -105.94M | -86.97M | -67.25M | 55.61M | -16.98M |
| Capital Expenditures | -1.71M | -5.5M | -1.28M | -650K | -1.35M | -2.69M |
| Acquisitions | n/a | -63.92M | 188.06M | 189.85M | 63K | n/a |
| Purchase of Investments | -129.9M | -219.53M | -537.74M | -293.86M | -79M | -4.99M |
| Sales Maturities Of Investments | 289.95M | 283.44M | 349.68M | 104M | 78.67M | 44.6M |
| Other Investing Acitivies | n/a | 63.92M | -188.06M | -189.85M | -271K | 39.61M |
| Investing Cash Flow | 158.35M | 58.42M | -189.34M | -190.5M | -1.62M | 36.92M |
| Debt Repayment | -12.5M | n/a | n/a | 11.97M | n/a | n/a |
| Common Stock Repurchased | -110K | n/a | n/a | -194K | -30K | -63K |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 426K | 1.15M | 1.94M | -3.45M | 274K | 1.91M |
| Financial Cash Flow | 45.49M | 1.15M | 171.4M | 348.93M | 244K | 1.96M |
| Net Cash Flow | 97M | -46.37M | -104.9M | 91.18M | 54.24M | 21.9M |
| Free Cash Flow | -108.55M | -111.44M | -88.24M | -67.9M | 54.27M | -19.67M |